These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32164767)

  • 1. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP).
    Gifford FJ; Dunne PDJ; Weir G; Ireland H; Graham C; Tuck S; Hayes PC; Fallowfield JA
    Trials; 2020 Mar; 21(1):260. PubMed ID: 32164767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.
    Snowdon VK; Lachlan NJ; Hoy AM; Hadoke PW; Semple SI; Patel D; Mungall W; Kendall TJ; Thomson A; Lennen RJ; Jansen MA; Moran CM; Pellicoro A; Ramachandran P; Shaw I; Aucott RL; Severin T; Saini R; Pak J; Yates D; Dongre N; Duffield JS; Webb DJ; Iredale JP; Hayes PC; Fallowfield JA
    PLoS Med; 2017 Feb; 14(2):e1002248. PubMed ID: 28245243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
    Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
    J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.
    Corcoran D; Radjenovic A; Mordi IR; Nazir SA; Wilson SJ; Hinder M; Yates DP; Machineni S; Alcantara J; Prescott MF; Gugliotta B; Pang Y; Tzemos N; Semple SI; Newby DE; McCann GP; Squire I; Berry C
    Cardiovasc Res; 2021 Jan; 117(1):320-329. PubMed ID: 32065620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J
    Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
    Chalasani N; Abdelmalek MF; Garcia-Tsao G; Vuppalanchi R; Alkhouri N; Rinella M; Noureddin M; Pyko M; Shiffman M; Sanyal A; Allgood A; Shlevin H; Horton R; Zomer E; Irish W; Goodman Z; Harrison SA; Traber PG;
    Gastroenterology; 2020 Apr; 158(5):1334-1345.e5. PubMed ID: 31812510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension.
    Schwarzer R; Kivaranovic D; Mandorfer M; Paternostro R; Wolrab D; Heinisch B; Reiberger T; Ferlitsch M; Gerner C; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Aliment Pharmacol Ther; 2018 Jan; 47(1):86-94. PubMed ID: 29105115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China.
    Liu C; Zhang L; Zhang S; Li X; Wong YJ; Liang X; Wang Y; Wu X; Gou W; Lv J; Hu S; Fu J; Huang J; Ge G; Huang M; Wang F; Zhang Q; Ren T; Meng Z; Ding D; Zhuoga B; Zhuoga C; Fan J; Dang D; Miao L; Song Z; Xiao X; Wu H; Jiang K; Liu T; Gao Y; Ma L; Fang T; Wang Y; Zhang Q; Zhu D; Ji D; Cao Z; Zeng QL; Li J; Chen P; Wei Y; Tong Z; Hong Z; Liang X; Li Y; Nan Y; Qi X
    BMJ Open; 2024 Jul; 14(7):e081623. PubMed ID: 38991669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
    Berzigotti A; Bellot P; De Gottardi A; Garcia-Pagan JC; Gagnon C; Spénard J; Bosch J
    Am J Gastroenterol; 2010 May; 105(5):1094-101. PubMed ID: 19920806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
    Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M
    Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
    Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
    Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.
    Weiss G; Teichman S; Stewart D; Nader D; Wood S; Breining P; Unemori E
    BMC Pregnancy Childbirth; 2016 Sep; 16(1):260. PubMed ID: 27596360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
    Bishnu S; Ahammed SM; Sarkar A; Hembram J; Chatterjee S; Das K; Dhali GK; Chowdhury A; Das K
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):54-59. PubMed ID: 29099421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis.
    Reiberger T; Berzigotti A; Trebicka J; Ertle J; Gashaw I; Swallow R; Tomisser A
    Trials; 2023 Apr; 24(1):293. PubMed ID: 37095557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension.
    Rittig N; Aagaard NK; Villadsen GE; Sandahl TD; Jessen N; Grønbaek H; George J
    Aliment Pharmacol Ther; 2021 Aug; 54(3):320-328. PubMed ID: 34165199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study.
    Reverter E; Mesonero F; Seijo S; Martínez J; Abraldes JG; Peñas B; Berzigotti A; Deulofeu R; Bosch J; Albillos A; García-Pagán JC
    Am J Gastroenterol; 2015 Jul; 110(7):985-92. PubMed ID: 26077176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial.
    Kemp W; Colman J; Thompson K; Madan A; Vincent M; Chin-Dusting J; Kompa A; Krum H; Roberts S
    Liver Int; 2009 Mar; 29(3):427-33. PubMed ID: 18673434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.
    Gupta N; Kumar A; Sharma P; Garg V; Sharma BC; Sarin SK
    Liver Int; 2013 Sep; 33(8):1148-57. PubMed ID: 23601333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.